

STIC-Biotech/ChemLib

116828

From: Hamud, Fozia  
Sent: Friday, March 12, 2004 4:29 PM  
To: STIC-Biotech/ChemLib  
Subject: sequence search for 09/997,514

Kindly search SEQ ID NO:422 of 09/997,514 against commercial and interference data bases. Thanks.

Fozia Hamud  
Patent Examiner  
Art Unit 1647  
Remsen, Room 4D64  
Mail Box Remsen-4C70  
272-0884

Searcher: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Location: \_\_\_\_\_  
Date Picked Up: 3/15/04  
Date Completed: 3/15/04  
Searcher Prep/Review: \_\_\_\_\_  
Clerical: \_\_\_\_\_  
Online time: \_\_\_\_\_

TYPE OF SEARCH:  
NA Sequences: \_\_\_\_\_  
AA Sequences: 1  
Structures: \_\_\_\_\_  
Bibliographic: \_\_\_\_\_  
Litigation: \_\_\_\_\_  
Full text: \_\_\_\_\_  
Patent Family: \_\_\_\_\_  
Other: \_\_\_\_\_

VENDOR/COST (where applic.)  
STN: \_\_\_\_\_  
DIALOG: \_\_\_\_\_  
Questel/Orbit: \_\_\_\_\_  
DRLink: \_\_\_\_\_  
Lexis/Nexis: \_\_\_\_\_  
Sequence Sys.: asp  
WWW/Internet: \_\_\_\_\_  
Other (specify): \_\_\_\_\_

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 15, 2004, 08:27:54 ; Search time 58 Seconds  
(without alignments)  
1919.374 Million cell updates/sec

Title: US-09-997-514-422

Perfect score: 2067  
Sequence: 1 MFCEPLKILFVLDYSLG.....RNNLEKKGSGGEMKTOQAF 394

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_28Jan04:\*  
1: geneseqp1980s:\*  
2: geneseqp1990s:\*  
3: geneseqp2000s:\*  
4: geneseqp2001s:\*  
5: geneseqp2002s:\*  
6: geneseqp2003as:\*  
7: geneseqp2003bs:\*  
8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2067	100.0	394	AA66764	Membrane-
2	2067	100.0	394	AB33454	AB33454 Human PRO
3	2067	100.0	394	AA94452	AA94452 Human inf
4	2067	100.0	394	AB24433	AB24433 Human PRO
5	2067	100.0	394	AAU12431	AAU12431 Human PRO
6	2067	100.0	394	AA38860	AA38860 Human pol
7	2067	100.0	394	AA65287	AA65287 Human PRO
8	2067	100.0	394	AA83689	AA83689 Human PRO
9	2067	100.0	394	AB84933	AB84933 Human PRO
10	2067	100.0	394	AB95539	AB95539 Human arg
11	2067	100.0	394	ABU58102	ABU58102 Human PRO
12	2067	100.0	394	ABU59180	ABU59180 Novel hum
13	2067	100.0	394	ABU82692	ABU82692 Human sec
14	2067	100.0	394	ABU17875	ABU17875 Novel hum
15	2067	100.0	394	ABU60611	ABU60611 Human sec
16	2067	100.0	394	ABU80836	ABU80836 Human PRO
17	2067	100.0	394	ABU33802	ABU33802 Novel hum
18	2067	100.0	394	ABU13993	ABU13993 Human PRO
19	2067	100.0	394	ABU81129	ABU81129 Human PRO
20	2067	100.0	394	ABU72578	ABU72578 Novel hum
21	2067	100.0	394	ABU66829	ABU66829 Human PRO
22	2067	100.0	394	ABU59910	ABU59910 Novel sec
23	2067	100.0	394	ABU59327	ABU59327 Human sec
24	2067	100.0	394	ABO26024	ABO26024 Human PRO
25	2067	100.0	394	ABO25100	ABO25100 Human sec

26	2067	100.0	394	ABU82145	ABU82145 Novel hum
27	2067	100.0	394	ABU59033	ABU59033 Human sec
28	2067	100.0	394	ABU92411	ABU92411 Novel hum
29	2067	100.0	394	ABU59476	ABU59476 Novel hum
30	2067	100.0	394	ABU67105	ABU67105 Human sec
31	2067	100.0	394	ABU92242	ABU92242 Novel hum
32	2067	100.0	394	ABU10948	ABU10948 Human PRO
33	2067	100.0	394	ABU81700	ABU81700 Novel hum
34	2067	100.0	394	ABU86639	ABU86639 Human sec
35	2067	100.0	394	ABO34153	ABO34153 Human PRO
36	2067	100.0	394	ADA46039	ADA46039 Novel hum
37	2067	100.0	394	ADA76470	ADA76470 Human PRO
38	2067	100.0	394	ABU72325	ABU72325 Human PRO
39	2067	100.0	394	ADA19120	ADA19120 Human PRO
40	2067	100.0	394	ADA61743	ADA61743 Homo sapi
41	2067	100.0	394	ADA19528	ADA19528 Novel hum
42	2067	100.0	394	ADA28065	ADA28065 Human PRO
43	2067	100.0	394	ADA86548	ADA86548 Novel hum
44	2067	100.0	394	ADA16112	ADA16112 Human PRO
45	2067	100.0	394	ADA37933	ADA37933 Human sec

## ALIGNMENTS

RESULT 1	ID	AA66764 standard; protein; 394 AA.
AC	AA66764;	
DT	05-APR-2000 (first entry)	
DE	Membrane-bound protein PRO1387.	
XX		
XX	Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;	
XX	pharmaceutical; receptor immunodhesin; gene mapping.	
XX		
OS	Homo sapiens.	
XX		
XX	MO9963088-A2.	
XX		
PD	09-DEC-1999.	
XX		
XX	02-JUN-1999;	99MO-US012252.
XX		
XX	02-JUN-1998;	98US-0087607P.
XX		
XX	02-JUN-1998;	98US-0087609P.
XX		
XX	02-JUN-1998;	98US-0087759P.
XX		
XX	03-JUN-1998;	98US-0087827P.
XX		
XX	04-JUN-1998;	98US-0088021P.
XX		
XX	04-JUN-1998;	98US-0088025P.
XX		
XX	04-JUN-1998;	98US-0088028P.
XX		
XX	04-JUN-1998;	98US-0088029P.
XX		
XX	04-JUN-1998;	98US-0088030P.
XX		
XX	04-JUN-1998;	98US-0088033P.
XX		
XX	04-JUN-1998;	98US-0088326P.
XX		
XX	05-JUN-1998;	98US-0088167P.
XX		
XX	05-JUN-1998;	98US-0088202P.
XX		
XX	05-JUN-1998;	98US-0088212P.
XX		
XX	05-JUN-1998;	98US-0088217P.
XX		
XX	09-JUN-1998;	98US-0088655P.
XX		
XX	10-JUN-1998;	98US-0088722P.
XX		
XX	10-JUN-1998;	98US-0088730P.
XX		
XX	10-JUN-1998;	98US-0088734P.
XX		
XX	10-JUN-1998;	98US-0088738P.
XX		
XX	10-JUN-1998;	98US-0088740P.
XX		
XX	10-JUN-1998;	98US-0088741P.
XX		
XX	10-JUN-1998;	98US-0088742P.
XX		
XX	10-JUN-1998;	98US-0088810P.
XX		
XX	10-JUN-1998;	98US-0088811P.
XX		
XX	10-JUN-1998;	98US-0088824P.
XX		
XX	10-JUN-1998;	98US-0088825P.

Sequence Comparison



Sequence Comparison  
1A

PR 10-JUN-1998; 98US-00888262;  
PR 11-JUN-1998; 98US-00888581;  
PR 11-JUN-1998; 98US-00888618;  
PR 11-JUN-1998; 98US-00888636;  
PR 11-JUN-1998; 98US-00888676;  
PR 12-JUN-1998; 98US-00890907;  
PR 12-JUN-1998; 98US-00894400;  
PR 16-JUN-1998; 98US-00895120;  
PR 16-JUN-1998; 98US-00895142;  
PR 17-JUN-1998; 98US-00895320;  
PR 17-JUN-1998; 98US-00895380;  
PR 17-JUN-1998; 98US-00895980;  
PR 17-JUN-1998; 98US-00895990;  
PR 17-JUN-1998; 98US-00896000;  
PR 17-JUN-1998; 98US-00896010;  
PR 18-JUN-1998; 98US-00896070;  
PR 18-JUN-1998; 98US-00896080;  
PR 19-JUN-1998; 98US-00896480;  
PR 19-JUN-1998; 98US-00896520;  
PR 22-JUN-1998; 98US-00902460;  
PR 22-JUN-1998; 98US-00902520;  
PR 22-JUN-1998; 98US-00902540;  
PR 22-JUN-1998; 98US-00903450;  
PR 22-JUN-1998; 98US-00903550;  
PR 22-JUN-1998; 98US-00903590;  
PR 24-JUN-1998; 98US-00904310;  
PR 24-JUN-1998; 98US-00904330;  
PR 24-JUN-1998; 98US-00904440;  
PR 24-JUN-1998; 98US-00904610;  
PR 24-JUN-1998; 98US-00904720;  
PR 24-JUN-1998; 98US-00905350;  
PR 24-JUN-1998; 98US-00905380;  
PR 24-JUN-1998; 98US-00905400;  
PR 25-JUN-1998; 98US-00905570;  
PR 25-JUN-1998; 98US-00906760;  
PR 25-JUN-1998; 98US-00906780;  
PR 25-JUN-1998; 98US-00906880;  
PR 25-JUN-1998; 98US-00906900;  
PR 25-JUN-1998; 98US-00906910;  
PR 25-JUN-1998; 98US-00906940;  
PR 25-JUN-1998; 98US-00906950;  
PR 25-JUN-1998; 98US-00906960;  
PR 26-JUN-1998; 98US-00908620;  
PR 26-JUN-1998; 98US-00908630;  
PR 01-JUL-1998; 98US-00913580;  
PR 01-JUL-1998; 98US-00913600;  
PR 02-JUL-1998; 98US-00914780;  
PR 02-JUL-1998; 98US-00914860;  
PR 02-JUL-1998; 98US-00915190;  
PR 02-JUL-1998; 98US-00915440;  
PR 02-JUL-1998; 98US-00916260;  
PR 02-JUL-1998; 98US-00916280;  
PR 02-JUL-1998; 98US-00916330;  
PR 02-JUL-1998; 98US-00916460;  
PR 02-JUL-1998; 98US-00916730;  
PR 07-JUL-1998; 98US-00917820;  
PR 07-JUL-1998; 98US-00918820;  
PR 09-JUL-1998; 98US-00921820;  
PR 10-JUL-1998; 98US-00924720;  
PR 20-JUL-1998; 98US-00933390;  
PR 30-JUL-1998; 98US-00946510;  
PR 04-AUG-1998; 98US-00952820;  
PR 04-AUG-1998; 98US-00953010;  
PR 04-AUG-1998; 98US-00953020;  
PR 04-AUG-1998; 98US-00953180;  
PR 04-AUG-1998; 98US-00953210;  
PR 04-AUG-1998; 98US-00953250;  
PR 10-AUG-1998; 98US-00955916P;

PR 10-AUG-1998; 98US-00953290;  
PR 10-AUG-1998; 98US-00960120;  
PR 11-AUG-1998; 98US-00961430;  
PR 11-AUG-1998; 98US-00961460;  
PR 12-AUG-1998; 98US-00963290;  
PR 17-AUG-1998; 98US-00967570;  
PR 17-AUG-1998; 98US-00967660;  
PR 17-AUG-1998; 98US-00967680;  
PR 17-AUG-1998; 98US-00967730;  
PR 17-AUG-1998; 98US-00967910;  
PR 17-AUG-1998; 98US-00968670;  
PR 17-AUG-1998; 98US-00968910;  
PR 17-AUG-1998; 98US-00968950;  
PR 17-AUG-1998; 98US-00968970;  
PR 18-AUG-1998; 98US-00968990;  
PR 18-AUG-1998; 98US-00969300;  
PR 18-AUG-1998; 98US-00969500;  
PR 18-AUG-1998; 98US-00969560;  
PR 18-AUG-1998; 98US-00970220;  
PR 19-AUG-1998; 98US-00971410;  
PR 20-AUG-1998; 98US-00972180;  
PR 24-AUG-1998; 98US-00976610;  
PR 26-AUG-1998; 98US-00979510;  
PR 26-AUG-1998; 98US-00979520;  
PR 26-AUG-1998; 98US-00979540;  
PR 26-AUG-1998; 98US-00979550;  
PR 26-AUG-1998; 98US-00979570;  
PR 26-AUG-1998; 98US-00979710;  
PR 26-AUG-1998; 98US-00979740;  
PR 26-AUG-1998; 98US-00979780;  
PR 26-AUG-1998; 98US-00979790;  
PR 26-AUG-1998; 98US-00980140;  
PR 31-AUG-1998; 98US-00985250;  
PR 16-SEP-1998; 98US-01006340;  
PR 12-JAN-1999; 98US-01155650;  
PR PA (GETH ) GENENTECH INC.  
PI Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;  
PI Wood WI, Yuan U;  
DR WPI: 2000-072883/06.  
DR N-PSDB: AAZ65110.  
XX Membrane-bound proteins and related nucleotide sequences.  
XX Claim 12: Fig 304; 822pp; English.  
XX The invention provides membrane-bound PRO polypeptides and  
CC polynucleotides encoding them. The PRO sequences of the invention were  
CC identified based on extracellular domain homology screening. The PRO  
CC sequences have homology with proteins including LDL receptors, TIR  
CC ligands and various enzymes. The membrane-bound proteins and receptor  
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor  
CC immunoadhesins, for instance, can be used as therapeutic agents to block  
CC receptor-ligand interactions. The membrane-bound proteins can also be  
CC employed for screening of potential peptide or small molecule inhibitors  
CC of the relevant receptor/ligand interaction. The PRO encoding sequences  
CC are useful as hybridization probes, in chromosome and gene mapping and in  
CC the generation of antisense RNA and DNA. PRO nucleic acid sequences will  
CC also be useful for the preparation of PRO polypeptides, especially by  
CC recombinant techniques  
XX  
XX Sequence 394 AA;  
SQ  
Query Match 100.0%; Score 2067; DB 3; Length 394;  
Best Local Similarity 100.0%; Pred. No. 5, 1e-188;  
Matches 394; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MFCPEKLLIPVLDVSLGINDINVSPEELTVHVDGSAIMGCVFQSTEDKCIFFIDWTLS 60  
DB 1 MFCPEKLLIPVLDVSLGINDINVSPEELTVHVDGSAIMGCVFQSTEDKCIFFIDWTLS 60

Sequence Comparison

QY 61 PGHNADEVLYYYNSLSPITGRFONRVHMGDILCNDGSLLDVDVADGTYICIRL 120  
 DB 61 PGHNADEVLYYYNSLSPITGRFONRVHMGDILCNDGSLLDVDVADGTYICIRL 120  
 QY 121 KESQVFKKAVVLYHLPPEPKELMHWVGLIQMGCVFQSTEVKATYKEMIFSGRAKEE 180  
 DB 121 KESQVFKKAVVLYHLPPEPKELMHWVGLIQMGCVFQSTEVKATYKEMIFSGRAKEE 180  
 QY 181 IYFRYHKLKRMSEVYSQSGHGNQKRVNIVGDIFFRDGSLIMQGVRESGQNYTSHLGN 240  
 DB 181 IYFRYHKLKRMSEVYSQSGHGNQKRVNIVGDIFFRDGSLIMQGVRESGQNYTSHLGN 240  
 QY 241 LVFKKTIIVHSPPEPRRTIVTPAALRPVLVGNQVIVIGVCAITILLPLILIVKTC 300  
 DB 241 LVFKKTIIVHSPPEPRRTIVTPAALRPVLVGNQVIVIGVCAITILLPLILIVKTC 300  
 QY 301 GKSSVNSTVLYKNTKNTPEIKKPCFPERGEGEKATYSPITREVIIEEPEPEKEAT 360  
 DB 301 GKSSVNSTVLYKNTKNTPEIKKPCFPERGEGEKATYSPITREVIIEEPEPEKEAT 360  
 QY 361 YMTMFVMPSLSDRNNSLEKSGGGMPTQOAF 394  
 DB 361 YMTMFVMPSLSDRNNSLEKSGGGMPTQOAF 394

AA33454  
 ID AAB33454 standard; protein; 394 AA.  
 AA33454;  
 29-JAN-2001 (first entry)  
 Human PRO1387 protein UNQ722 SEQ ID NO:187.  
 Human; immune related disease; diagnosis; antiinflammatory; cardiac;  
 dermatological; antiarthritic; antirheumatic; immunosuppressive;  
 haemostatic; antihypertensive; antidiabetic; neuroprotective;  
 antineoplastic; hepatotropic; virucide; antiparasitic; antiallergic;  
 antiscabetic; systemic lupus erythematosus; rheumatoid arthritis;  
 idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;  
 systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;  
 autoimmune thrombocytopenia; immune-mediated renal disease;  
 demyelinating disease; hepatobiliary disease; Whipple's disease;  
 inflammatory bowel disease; gluten-sensitive enteropathy;  
 autoimmune disease; immune-mediated skin disease; allergic disease;  
 immunological disease; transplantation associated disease;  
 graft rejection; graft-versus-host-disease.  
 Homo sapiens.  
 OS  
 PN WO200053758-A2.  
 PD 14-SEP-2000.  
 XX 02-MAR-2000; 2000WO-US005841.  
 XX 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99US-0123618P.  
 PR 12-MAR-1999; 99US-0123957P.  
 PR 23-MAR-1999; 99US-0125775P.  
 PR 12-APR-1999; 99US-0128645P.  
 PR 20-APR-1999; 99WO-US006615.  
 PR 28-APR-1999; 99US-0131445P.  
 PR 04-MAY-1999; 99US-0132371P.  
 PR 14-MAY-1999; 99US-0134287P.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 23-JUN-1999; 99US-0141037P.  
 PR 20-JUL-1999; 99US-0144758P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.

PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-OCT-1999; 99US-0162506P.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028213.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028851.  
 PR 02-DEC-1999; 99WO-US028854.  
 PR 02-DEC-1999; 99WO-US028855.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.

(GENTH ) GENENTECH INC.

Ashtkenazi AJ, Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W, Kabakoff RC, Lu Y, Pan J, Pennica D, Shelton DL, Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Yan M, WPI; 2000-572271/53.

DR N-PSDB; AAC58619.

PT Sixty four PRO polypeptides, useful in the diagnosis and treatment of immune related disorders, e.g. systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, thyroiditis and diabetes mellitus.

PS Claim 33, Fig 82, 309pp; English.

XX The present invention describes sixty four human PRO proteins which can be used in the treatment of immune related diseases. The human PRO proteins, anti-PRO antibodies, agonists and antagonists are useful for treating and diagnosing immune related disorders. The disorders are selected from systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, demyelinating diseases of the central and peripheral nervous systems, hepatobiliary diseases, inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune or immune-mediated skin diseases, allergic diseases, immunological diseases of the lung, and transplantation associated diseases including graft rejection and graft-versus-host-disease. AAC58397 to AAC58578 represent PCR primers and hybridisation probe used in the isolation of human PRO sequences. AAC58579 to AAC58642 and AAB33414 to AAB33477 represent human PRO polynucleotide and protein sequences given in the exemplification of the present invention

XX Sequence 394 AA;

Query Match 100.0%; Score 2067; DB 3; Length 394;  
 Best Local Similarity 100.0%; Pred. No. 5, 1e-188;  
 Matches 394; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MFCEPKLILPVLDYSGINDLVSPPELTVMVGSALMGCVFQSTEDKCIKIDMTWS 60  
 DB 1 MFCEPKLILPVLDYSGINDLVSPPELTVMVGSALMGCVFQSTEDKCIKIDMTWS 60  
 QY 61 PGHNADEVLYYYNSLSPITGRFONRVHMGDILCNDGSLLDVDVADGTYICIRL 120

Db 61 PGEHAKDEVLYYYNSLSPVIGRFQNRVHLMGDIICNDGSLLDQVGEADOGTYICEIRL 120  
 Qy 121 KGESQVFKKAVLVHLVPEEPKELMVAHVGGLIOMGCVFQSTEVKHTKVMIFSGRAKEE 180  
 Db 121 KGESQVFKKAVLVHLVPEEPKELMVAHVGGLIOMGCVFQSTEVKHTKVMIFSGRAKEE 180  
 Qy 181 IYFRYYHKLMSVEYSQSGWHFQNRVNLVGDIFRNDGSLMLGVRESQDGNITCSIHLEN 240  
 Db 181 IYFRYYHKLMSVEYSQSGWHFQNRVNLVGDIFRNDGSLMLGVRESQDGNITCSIHLEN 240  
 Qy 241 LVFKKTIIVLHVSPEEPRTLVTPALRPVLVGNQVVIIVGIVCATILLPVLLIVKTC 300  
 Db 241 LVFKKTIIVLHVSPEEPRTLVTPALRPVLVGNQVVIIVGIVCATILLPVLLIVKTC 300  
 Qy 301 GNKSSVNSTVLVKNKTNPEIKERPCHEGCEGKHYSPIIVREVIIEEPESEKSEAT 360  
 Db 301 GNKSSVNSTVLVKNKTNPEIKERPCHEGCEGKHYSPIIVREVIIEEPESEKSEAT 360  
 Qy 361 YMTMHPVWPSLRSDRNNSLKKSGGGMPKTOQAF 394  
 Db 361 YMTMHPVWPSLRSDRNNSLKKSGGGMPKTOQAF 394

## RESULT 3

AAV94452  
 ID AAV94452 standard; protein; 394 AA.

XX AAV94452;  
 AC AAV94452;

DT 11-SEP-2000 (first entry)

DE Human inflammation associated protein #11.

KM Inflammation; rheumatoid arthritis; Crohn's disease; asthma;  
 KW multiple sclerosis; allergy; AIDS; diabetes mellitus antinflammatory;  
 KM gene therapy; human.

OS Homo sapiens.

PN WO200029574-A2.

PD 25-MAY-2000.

PF 04-NOV-1999; 99WO-US026234.

PR 18-NOV-1998; 98US-00195292.

PA (INCYTE) INCYTE PHARM INC.

PI Walker MG, Volkman W, Klingler TM;

DR WPI; 2000-38787/33.

DR N-PSDB; AAA27133.

PT New human inflammation-associated polypeptide useful for diagnosis,  
 PT prevention and treatment of inflammatory diseases comprises product of  
 PT gene coexpressed with e.g. CD16, L-selectin and IP-30.

PS Claim 4; Page 42-43; 43pp; English.

CC Eleven novel inflammation-associated genes have been identified in cDNA  
 CC libraries from various tissues. The genes were selected according to  
 CC their coexpression with the known inflammation genes, CD16, L-selectin,  
 CC Src-like adapter protein, IP-30, superoxide homoenzyme subunits, alpha-  
 CC 1-antitrypsin, C1q-A, 5-lipoxygenase activating protein and SRC family  
 CC tyrosine kinase. The novel polynucleotides may be used in hybridization  
 CC assays to diagnose a disease or condition associated with altered  
 CC expression of the inflammation genes. Antibodies against the genes may be  
 CC useful in compositions for the diagnosis and treatment of such diseases  
 CC associated with inflammation including rheumatoid arthritis, Crohn's  
 CC disease, multiple sclerosis, AIDS, diabetes mellitus, asthma and allergy.  
 CC Additionally the polynucleotides of the invention may be used for gene  
 CC therapy. The present sequence is human inflammation associated protein

CC #11, derived from Incyte Clone 3507924  
 XX Sequence 394 AA;  
 SQ Query Match 100.0%; Score 2067; DB 3; Length 394;  
 Best Local Similarity 100.0%; Pred. No. 5.1e-188;  
 Matches 394; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MPEPLKILLPLVLLDLSGLNDLNVSPPELTVHVGDSALMGCVQSTEDKCFKIDWTLS 60  
 Db 1 MPEPLKILLPLVLLDLSGLNDLNVSPPELTVHVGDSALMGCVQSTEDKCFKIDWTLS 60  
 Qy 61 PGEHAKDEVLYYYNSLSPVIGRFQNRVHLMGDIICNDGSLLDQVGEADOGTYICEIRL 120  
 Db 61 PGEHAKDEVLYYYNSLSPVIGRFQNRVHLMGDIICNDGSLLDQVGEADOGTYICEIRL 120  
 Qy 121 KGESQVFKKAVLVHLVPEEPKELMVAHVGGLIOMGCVFQSTEVKHTKVMIFSGRAKEE 180  
 Db 121 KGESQVFKKAVLVHLVPEEPKELMVAHVGGLIOMGCVFQSTEVKHTKVMIFSGRAKEE 180  
 Qy 181 IYFRYYHKLMSVEYSQSGWHFQNRVNLVGDIFRNDGSLMLGVRESQDGNITCSIHLEN 240  
 Db 181 IYFRYYHKLMSVEYSQSGWHFQNRVNLVGDIFRNDGSLMLGVRESQDGNITCSIHLEN 240  
 Qy 241 LVFKKTIIVLHVSPEEPRTLVTPALRPVLVGNQVVIIVGIVCATILLPVLLIVKTC 300  
 Db 241 LVFKKTIIVLHVSPEEPRTLVTPALRPVLVGNQVVIIVGIVCATILLPVLLIVKTC 300  
 Qy 301 GNKSSVNSTVLVKNKTNPEIKERPCHEGCEGKHYSPIIVREVIIEEPESEKSEAT 360  
 Db 301 GNKSSVNSTVLVKNKTNPEIKERPCHEGCEGKHYSPIIVREVIIEEPESEKSEAT 360  
 Qy 361 YMTMHPVWPSLRSDRNNSLKKSGGGMPKTOQAF 394  
 Db 361 YMTMHPVWPSLRSDRNNSLKKSGGGMPKTOQAF 394

## RESULT 4

AAAB24433  
 ID AAB24433 standard; protein; 394 AA.

AC AAB24433;  
 AC AAB24433;

DT 07-NOV-2000 (first entry)

DE Human PRO1387 protein sequence SEQ ID NO:220.

KM Human; PRO; promotion; inhibition; angiogenesis; cardiovascularisation;  
 KW diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy;  
 KW angiogenic; proliferative; cardiant; cardiovascular; antithrombotic;  
 KM cytoskeletal; gene therapy; vaccine.

OS Homo sapiens.

PN WO200032221-A2.

PD 08-JUN-2000.

PF 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1998; 98WO-US025108.

PR 16-DEC-1998; 98US-0112850P.

PR 12-JAN-1999; 99US-0115554P.

PR 08-MAR-1999; 99WO-US005028.

PR 12-MAR-1999; 99US-0123957P.

PR 28-APR-1999; 99US-0131445P.

PR 14-MAY-1999; 99US-0134287P.

PR 02-JUN-1999; 99WO-US012252.

PR 23-JUN-1999; 99US-0141037P.  
 PR 20-JUL-1999; 99US-0144758P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.

sequence confirmed

# Sequence Comparison

13-SEP-1999; 99WO-US020944.  
 15-SEP-1999; 99WO-US021090.  
 15-SEP-1999; 99WO-US021547.  
 05-OCT-1999; 99WO-US023089.  
 29-OCT-1999; 99US-0162506P.  
 (GETH) GENENTECH INC.  
 Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillan KJ, Goddard A, Godowski PJ, Gurney AL, Klein RD, Kuo SS, Paoni NF, Smith V, Watanabe CK, Williams FM, Wood WI;  
 MPI; 2000-412154/35.  
 N-PSDB; AA077683.  
 Nucleic acids encoding PRO polypeptides useful for preventing, diagnosing and treating a cardiovascular, endothelial or angiogenic disorders in mammals.  
 Claim 72; Fig 92; 315pp; English.

The present invention describes nucleic acids encoding PRO polypeptides useful for preventing, diagnosing and treating disorders in mammals by cardiovascular, endothelial or angiogenic disorder in mammals by modulating cell proliferation, angiogenesis and cardiovascularization, and for identifying agonists and antagonists of these processes. The nucleic acids and the proteins they encode may be used in the prevention, treatment and diagnosis of diseases associated with inappropriate PRO expression such as cardiovascular, endothelial or angiogenic disorders in mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For example, the nucleic acids (NCs) and vectors containing them and the PRO polypeptide may be used to treat disorders associated with decreased PRO expression. AA077510 to AA077721 and AA024388 to AA024435 represent CC nucleotide and protein sequences used in the exemplification of the present invention

Sequence 394 AA:

Query Match 100.0%; Score 2067; DB 3; Length 394;  
 Best Local Similarity 100.0%; Pred. No. 5,1e-188;  
 Matches 394; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MFCPLKLLPVLVLSGLNDLNSPELTVHVDASALMGCVFQSTEDKCFKIDWTL 60  
 1 MFCPLKLLPVLVLSGLNDLNSPELTVHVDASALMGCVFQSTEDKCFKIDWTL 60  
 61 PGEHADVLYLYYNSLSPVIFGRFQNRVHMGDILCNGSLLDVGADGTCIRL 120  
 61 PGEHADVLYLYYNSLSPVIFGRFQNRVHMGDILCNGSLLDVGADGTCIRL 120  
 121 KGSQVFKAAVLYLPEPKELMTHVGLIOMGCVFQSTEDKCFKIDWTL 180  
 121 KGSQVFKAAVLYLPEPKELMTHVGLIOMGCVFQSTEDKCFKIDWTL 180  
 181 IYFRYHKLKMSVYSQSGWGHQNRVNTVGDIFRDSGIMOGVRESGNYTSHLGN 240  
 181 IYFRYHKLKMSVYSQSGWGHQNRVNTVGDIFRDSGIMOGVRESGNYTSHLGN 240  
 241 LVFKKTIIVHVSSEPRITVTPALRPLVLAGNQLVIVGIVCANILLPVLIVKTC 300  
 241 LVFKKTIIVHVSSEPRITVTPALRPLVLAGNQLVIVGIVCANILLPVLIVKTC 300  
 301 GNKSSVNSVTVLVNKKINPEIKKPCFRCCEGKHIYSPIVREVEEPESEKSDAT 360  
 301 GNKSSVNSVTVLVNKKINPEIKKPCFRCCEGKHIYSPIVREVEEPESEKSDAT 360  
 361 YMTMHPVWPELRSDRNLSLEKSGGGMPTQOAF 394  
 361 YMTMHPVWPELRSDRNLSLEKSGGGMPTQOAF 394

RESULT 5  
 AA012431

ID AA012431 standard; protein; 394 AA.  
 AC AA012431;  
 XX 24-OCT-2001 (first entry)  
 DT 24-OCT-2001 (first entry)  
 DE Human PRO1387 polypeptide sequence.  
 XX Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte; A-peptide; factor VIIA; gene therapy.  
 XX Homo sapiens.  
 XX WO200140466-A2.  
 PN 07-JUN-2001.  
 PD 07-JUN-2001.  
 PF 01-DEC-2000; 2000WO-US032678.  
 XX 01-DEC-1999; 99WO-US028301.  
 XX 01-DEC-1999; 99WO-US028634.  
 XX 02-DEC-1999; 99WO-US028551.  
 XX 02-DEC-1999; 99WO-US028564.  
 XX 02-DEC-1999; 99WO-US028565.  
 XX 09-DEC-1999; 99US-0170262P.  
 XX 16-DEC-1999; 99WO-US030095.  
 XX 16-DEC-1999; 99WO-US030911.  
 XX 20-DEC-1999; 99WO-US030939.  
 XX 30-DEC-1999; 99WO-US031243.  
 XX 30-DEC-1999; 99WO-US031274.  
 XX 03-DEC-1999; 2000WO-US000219.  
 XX 05-JAN-2000; 2000WO-US000277.  
 XX 06-JAN-2000; 2000WO-US000376.  
 XX 11-FEB-2000; 2000WO-US0003565.  
 XX 18-FEB-2000; 2000WO-US0004342.  
 XX 18-FEB-2000; 2000WO-US0004342.  
 XX 22-FEB-2000; 2000WO-US0004414.  
 XX 24-FEB-2000; 2000WO-US0004914.  
 XX 24-FEB-2000; 2000WO-US0005004.  
 XX 01-MAR-2000; 2000WO-US000501.  
 XX 02-MAR-2000; 2000WO-US0005841.  
 XX 03-MAR-2000; 2000US-0187202P.  
 XX 10-MAR-2000; 2000WO-US006319.  
 XX 15-MAR-2000; 2000WO-US006884.  
 XX 20-MAR-2000; 2000WO-US007377.  
 XX 21-MAR-2000; 2000WO-US007532.  
 XX 30-MAR-2000; 2000WO-US008439.  
 XX 17-MAY-2000; 2000WO-US013705.  
 XX 22-MAY-2000; 2000WO-US014042.  
 XX 30-MAY-2000; 2000WO-US014941.  
 XX 02-JUN-2000; 2000WO-US015264.  
 XX 05-JUN-2000; 2000US-0209832P.  
 XX 28-JUL-2000; 2000WO-US020710.  
 XX 11-AUG-2000; 2000WO-US022031.  
 XX 23-AUG-2000; 2000WO-US023522.  
 XX 24-AUG-2000; 2000WO-US023328.  
 XX 08-NOV-2000; 2000WO-US030952.  
 XX 10-NOV-2000; 2000WO-US030873.  
 PA (GETH) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W, Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S, Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 MPI; 2001-408281/43.  
 DR N-PSDB; AA021503.  
 PT Isolated, secretory and transmembrane PRO polypeptide used to detect other PRO polypeptides, link bioactive molecules to cells expressing PRO polypeptides, and detect the presence of mammalian tumors e.g. lung,

Sequence Comparison

Db 61 PGEHAKDEYLVYYNSVPIGRFQNRVHLMGDIICNDGSLILDVQADQGTICETRL 120  
 QY 121 KGESQVFKKAVLVHLEPEEKELMWHVGGIIONGCVFQSTEVKHYTKVEMISGRAXEE 180  
 Db 121 KGESQVFKKAVLVHLEPEEKELMWHVGGIIONGCVFQSTEVKHYTKVEMISGRAXEE 180  
 QY 181 IVPFHYHKLMSVYSOSMGHFORVNLVGDIFRNDGIMLQGVESDGNVTSIHIGN 240  
 Db 181 IVPFHYHKLMSVYSOSMGHFORVNLVGDIFRNDGIMLQGVESDGNVTSIHIGN 240  
 QY 241 LVFKKTIIVHVSPEEPRTLVTPALRPLVGGNOLVIVGIVCATILLPVLILVKKTC 300  
 Db 241 LVFKKTIIVHVSPEEPRTLVTPALRPLVGGNOLVIVGIVCATILLPVLILVKKTC 300  
 QY 301 GNKSVNSTVLVVKTKTNPEIKKPCHEFCGEGKHVSPITVREVIIEEPESEKSEAT 360  
 Db 301 GNKSVNSTVLVVKTKTNPEIKKPCHEFCGEGKHVSPITVREVIIEEPESEKSEAT 360  
 QY 361 YMTMHPVWPSLRSDRNSLEKSGGGMPTQOAF 394  
 Db 361 YMTMHPVWPSLRSDRNSLEKSGGGMPTQOAF 394

RESULT 3  
 ID AAY94452 standard; protein; 394 AA.  
 AC AAY94452;  
 DT 11-SEP-2000 (first entry)  
 DE Human inflammation associated protein #11.  
 XX  
 KM Inflammation; rheumatoid arthritis; Crohn's disease; asthma;  
 KM multiple sclerosis; allergy; AIDS; diabetes mellitus antiinflammatory;  
 KM gene therapy; human.  
 OS Homo sapiens.  
 PN W0200029574-A2.  
 PD 25-MAY-2000.  
 XX  
 FE 04-NOV-1999; 99WO-US026234.  
 PR 18-NOV-1998; 98US-00195292.  
 XX  
 PA (INCYTE-) INCYTE PHARM INC.  
 PI Walker MG, Volkman W, Klingler TM;  
 DR WPI: 2000-387787/33.  
 DR N-PSDB; AAA27133.  
 PT New human inflammation-associated polypeptide useful for diagnosis,  
 PT prevention and treatment of inflammatory diseases comprises product of  
 PT gene coexpressed with e.g. CD16, L-selectin and IP-30.  
 XX  
 PS Claim 4; Page 42-43; 43pp; English.

Eleven novel inflammation-associated genes have been identified in cDNA  
 libraries from various tissues. The genes were selected according to  
 their coexpression with the known inflammation genes, CD16, L-selectin,  
 Src-like adapter protein, IP-30, superoxide homoenzyme subunits, alpha-  
 1-antitrypsin, C1q-A, 5-lipoxygenase activating protein and SRC family  
 tyrosine kinase. The novel polynucleotides may be used in hybridization  
 assays to diagnose a disease or condition associated with altered  
 expression of the inflammation genes. Antibodies against the genes may be  
 useful in compositions for the diagnosis and treatment of such diseases  
 associated with inflammation including rheumatoid arthritis, Crohn's  
 disease, multiple sclerosis, AIDS, diabetes mellitus, asthma and allergy.  
 Additionally the polynucleotides of the invention may be used for gene  
 therapy. The present sequence is human inflammation associated protein

Sequence Comparison

CC #11, derived from Incyte Clone 3507924  
 XX  
 SQ Sequence 394 AA;  
 Query Match 100.0%; Score 2067; DB 3; Length 394;  
 Best Local Similarity 100.0%; Pred. No. 5, 1e-188;  
 Matches 394; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MFCEPLKILLVLLDYSIGLNDLVSPPELTVAHVSALMGCVFQSTEDKCFKIDWTIS 60  
 Db 1 MFCEPLKILLVLLDYSIGLNDLVSPPELTVAHVSALMGCVFQSTEDKCFKIDWTIS 60  
 QY 61 PGEHAKDEYLVYYNSVPIGRFQNRVHLMGDIICNDGSLILDVQADQGTICETRL 120  
 Db 61 PGEHAKDEYLVYYNSVPIGRFQNRVHLMGDIICNDGSLILDVQADQGTICETRL 120  
 QY 121 KGESQVFKKAVLVHLEPEEKELMWHVGGIIONGCVFQSTEVKHYTKVEMISGRAXEE 180  
 Db 121 KGESQVFKKAVLVHLEPEEKELMWHVGGIIONGCVFQSTEVKHYTKVEMISGRAXEE 180  
 QY 181 IVPFHYHKLMSVYSOSMGHFORVNLVGDIFRNDGIMLQGVESDGNVTSIHIGN 240  
 Db 181 IVPFHYHKLMSVYSOSMGHFORVNLVGDIFRNDGIMLQGVESDGNVTSIHIGN 240  
 QY 241 LVFKKTIIVHVSPEEPRTLVTPALRPLVGGNOLVIVGIVCATILLPVLILVKKTC 300  
 Db 241 LVFKKTIIVHVSPEEPRTLVTPALRPLVGGNOLVIVGIVCATILLPVLILVKKTC 300  
 QY 301 GNKSVNSTVLVVKTKTNPEIKKPCHEFCGEGKHVSPITVREVIIEEPESEKSEAT 360  
 Db 301 GNKSVNSTVLVVKTKTNPEIKKPCHEFCGEGKHVSPITVREVIIEEPESEKSEAT 360  
 QY 361 YMTMHPVWPSLRSDRNSLEKSGGGMPTQOAF 394  
 Db 361 YMTMHPVWPSLRSDRNSLEKSGGGMPTQOAF 394

RESULT 4  
 ID AAB24433 standard; protein; 394 AA.  
 AC AAB24433;  
 DT 07-NOV-2000 (first entry)  
 DE Human PRO1387 protein sequence SEQ ID NO:220.  
 XX  
 KM Human; PRO; promotion; inhibition; angiogenesis; cardiovascularisation;  
 KM diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy;  
 KM angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic;  
 KM cytostatic; gene therapy; vaccine.  
 OS Homo sapiens.  
 PN W0200032221-A2.  
 PD 08-JUN-2000.  
 XX  
 PR 30-NOV-1999; 99WO-US028313.  
 XX  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 16-DEC-1998; 98US-0112850P.  
 PR 12-JAN-1999; 99US-0115554P.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 12-MAR-1999; 99US-0123957P.  
 PR 28-APR-1999; 99US-013445P.  
 PR 14-MAY-1999; 99US-0134287P.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 23-JUN-1999; 99US-0141037P.  
 PR 20-JUL-1999; 99US-0144758P.  
 PR 26-JUL-1999; 99US-0144698P.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.